(Q46726145)
Statements
Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations (English)
Susumu Kobayashi
1182-4; author reply 1184-6